Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Pain 3Peripheral Nervous System Diseases 1Neurotoxicity Syndromes 1Neoplasms 1Multiple Myeloma 1Mucositis 1Lymphoma 1Intraoperative Complications 1Head and Neck Neoplasms 1Chronic Pain 1Cancer Pain 1Abnormalities, Radiation-Induced 1

Interventions

Cisplatin 252Radiotherapy 176Cetuximab 144pembrolizumab 120Docetaxel 96Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Gefitinib 21Cyclophosphamide 21Surveys and Questionnaires 20Surgical Procedures, Operative 19Standard of Care 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15Low-Level Light Therapy 14Everolimus 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × Pain Management × Clear all
NCT02480114 2021-02-18

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
79 enrolled 8 charts
Head & NeckOther

Abnormalities, Radiation-Induced, Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡